AbCellera Biologics Q3 Earnings Expected to Take a Hit
October 28, 2023
🌥️Trending News
ABCELLERA ($NASDAQ:ABCL): AbCellera Biologics Inc. is a biotechnology company based in Vancouver, Canada that specializes in the development of antibody-based therapies for diseases. As one of the rising stars in the biotechnology industry, the company has seen a great deal of success and growth in recent years.
However, its Q3 earnings are expected to take a hit. This is mainly due to the disruption caused by the pandemic, which has caused many of the company’s operations to be delayed or disrupted.
Additionally, the company’s investments in research and development have also been affected, leading to an overall decrease in earnings. The company’s stock price has also been affected by the expected drop in earnings. Analysts predict that the stock price will continue to decline in the near future as investors become more cautious about investing in the company. Investors are advised to be cautious and examine the potential risks before investing in the company’s stock.
Earnings
The report revealed a total revenue of 27.64M USD, with a net income loss of 2.32M USD. This represented a 39.8% decrease in total revenue compared to the same period the previous year. Over the last 3 years, ABCELLERA BIOLOGICS‘s total revenue has decreased from 27.64M USD to 10.06M USD. This significant decrease in total revenue may be an indication of a tough Q3 earnings performance for the company.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abcellera Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 145.18 | -73.91 | -50.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abcellera Biologics. More…
| Operations | Investing | Financing |
| -120.03 | -483.06 | 0.29 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 342.34 | 4.14 |
Key Ratios Snapshot
Some of the financial key ratios for Abcellera Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 247.1% | 541.4% | -60.9% |
| FCF Margin | ROE | ROA |
| -130.2% | -4.6% | -3.6% |
Price History
AbCellera Biologics Inc. is set to take a hit in its third quarter earnings, as their stock opened at $4.2 and closed at $3.9 on the Friday before the release of their earnings report. This marks a 5.6% decrease from the previous closing price of $4.1. Investors are expecting that this drop in the stock price is a reflection of AbCellera’s performance for the quarter. How the company fares within the third quarter remains to be seen, but investors will certainly be keeping a close eye on the results of this earnings report. Live Quote…
Analysis
At GoodWhale, we conducted an analysis of ABCELLERA BIOLOGICS‘s fundamentals. After reviewing the Star Chart, we concluded that ABCELLERA BIOLOGICS is classified as an ‘elephant’, which signifies that the company has a large number of assets to deduct liabilities from. Investors who are interested in such a company are likely to be long-term and hold a diversified portfolio, as ABCELLERA BIOLOGICS has both strong assets and growth prospects. In addition, ABCELLERA BIOLOGICS has a very high health score of 8/10 with respect to its cashflows and debt. This indicates that the company is well-positioned to ride out any crisis without the risk of bankruptcy. Furthermore, ABCELLERA BIOLOGICS is strong in asset and growth opportunities but weak in dividend yields. Nevertheless, it still has a respectable level of profitability, making it an attractive option for investors. More…
Peers
Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.
– Ensysce Biosciences Inc ($NASDAQ:ENSC)
Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.
– INmune Bio Inc ($NASDAQ:INMB)
Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.
Summary
AbCellera Biologics Inc., a biotechnology company, is set to report their third quarter earnings in the coming weeks. Analysts predict that the company’s earnings will decline compared to the same period last year. This news has caused their stock price to drop on the day it was announced. Investors should closely monitor the financial results of AbCellera Biologics when they are released as this could give insight into their long-term prospects.
In addition, be sure to pay close attention to any changes in their research and development strategy, as this could affect their future revenue and earnings performance. Those considering investing in AbCellera Biologics should analyze the company’s financials and evaluate how their underlying fundamentals have changed over time. It is also important to consider the wider economic environment when assessing AbCellera Biologics’ stock price, as market conditions can have a significant impact on the share price. Ultimately, investors should use all available information to make an informed decision before investing in AbCellera Biologics.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
